Centre for Medical Imaging, University College London, 2nd Floor, Charles Bell House, 43-45 Foley Street, London, W1W 7TS, UK.
NIHR In Vitro Diagnostics Co-operative, Newcastle University, Newcastle upon Tyne, NE2 7RU, UK.
BMC Med. 2020 Nov 4;18(1):346. doi: 10.1186/s12916-020-01810-8.
Tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral ribonucleic acid (RNA) using reverse transcription polymerase chain reaction (RT-PCR) are pivotal to detecting current coronavirus disease (COVID-19) and duration of detectable virus indicating potential for infectivity.
We conducted an individual participant data (IPD) systematic review of longitudinal studies of RT-PCR test results in symptomatic SARS-CoV-2. We searched PubMed, LitCOVID, medRxiv, and COVID-19 Living Evidence databases. We assessed risk of bias using a QUADAS-2 adaptation. Outcomes were the percentage of positive test results by time and the duration of detectable virus, by anatomical sampling sites.
Of 5078 studies screened, we included 32 studies with 1023 SARS-CoV-2 infected participants and 1619 test results, from - 6 to 66 days post-symptom onset and hospitalisation. The highest percentage virus detection was from nasopharyngeal sampling between 0 and 4 days post-symptom onset at 89% (95% confidence interval (CI) 83 to 93) dropping to 54% (95% CI 47 to 61) after 10 to 14 days. On average, duration of detectable virus was longer with lower respiratory tract (LRT) sampling than upper respiratory tract (URT). Duration of faecal and respiratory tract virus detection varied greatly within individual participants. In some participants, virus was still detectable at 46 days post-symptom onset.
RT-PCR misses detection of people with SARS-CoV-2 infection; early sampling minimises false negative diagnoses. Beyond 10 days post-symptom onset, lower RT or faecal testing may be preferred sampling sites. The included studies are open to substantial risk of bias, so the positivity rates are probably overestimated.
使用逆转录聚合酶链反应 (RT-PCR) 检测严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 病毒核糖核酸 (RNA) 对于检测当前的冠状病毒病 (COVID-19) 和可检测病毒的持续时间以指示潜在传染性至关重要。
我们对有症状的 SARS-CoV-2 的 RT-PCR 检测结果进行了个体参与者数据 (IPD) 系统评价。我们搜索了 PubMed、LitCOVID、medRxiv 和 COVID-19 Living Evidence 数据库。我们使用 QUADAS-2 改编版评估了偏倚风险。结果是按时间和解剖采样部位计算的阳性检测结果的百分比和可检测病毒的持续时间。
在筛选出的 5078 项研究中,我们纳入了 32 项研究,共纳入了 1023 名 SARS-CoV-2 感染患者和 1619 项检测结果,发病后至住院时间为 6 至 66 天。从症状发作后 0 至 4 天的鼻咽采样中检测到的病毒最高百分比为 89%(95%置信区间 [CI] 83 至 93),在 10 至 14 天后降至 54%(95% CI 47 至 61)。平均而言,下呼吸道 (LRT) 采样的病毒检测持续时间比上呼吸道 (URT) 采样长。粪便和呼吸道病毒检测的持续时间在个体参与者内差异很大。在一些参与者中,症状发作后 46 天仍可检测到病毒。
RT-PCR 会错过对 SARS-CoV-2 感染者的检测;早期采样可最大限度地减少假阴性诊断。在症状发作后 10 天以上,可能更倾向于选择下呼吸道或粪便检测。纳入的研究存在很大的偏倚风险,因此阳性率可能被高估。